Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130)

Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130) ( SPD-M196b), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK 293

Origin Species

Mouse

Target

Spike RBD

Conjugation

Unconjugated

Tag

Human IgA2 | Human Kappa

Stability

For long term storage, the product is stable for up to 3 years at -70°C from date of receipt; For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt._x000D_After reconstitution, this product is stable after storage at -20°C or lower._x000D_Please avoid repeated freeze-thaw cycles.

Purity

95%

Bioactivity

Immobilized SARS-CoV-2 S protein RBD, His Tag(Cat. No. SPD-C52H1) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130) (Cat. No. SPD-M196b) with a linear range of 0.2-4.8ng/mL (QC tested)